BRAF+ melanoma: adjuvant dabrafenib/trametinib boosts DFS

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Adjuvant therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist) is associated with reduced recurrence risk in patients with stage III melanoma with BRAF V600 mutations.

Why this matters

  • Dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, have each been lin...